KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $618000.0.

  • Nektar Therapeutics' Other Working Capital Changes fell 8272.78% to $618000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 20506.09%. This contributed to the annual value of $4.2 million for FY2024, which is 21685.74% up from last year.
  • Latest data reveals that Nektar Therapeutics reported Other Working Capital Changes of $618000.0 as of Q3 2025, which was down 8272.78% from -$985000.0 recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Other Working Capital Changes high stood at $10.8 million for Q3 2021, and its period low was -$6.2 million during Q1 2021.
  • Over the past 5 years, Nektar Therapeutics' median Other Working Capital Changes value was $618000.0 (recorded in 2025), while the average stood at $98684.2.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first crashed by 16014.71% in 2022, then soared by 51045.08% in 2025.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Other Working Capital Changes stood at $3.4 million in 2021, then crashed by 160.15% to -$2.0 million in 2022, then soared by 142.4% to $867000.0 in 2023, then skyrocketed by 179.82% to $2.4 million in 2024, then plummeted by 74.53% to $618000.0 in 2025.
  • Its Other Working Capital Changes stands at $618000.0 for Q3 2025, versus -$985000.0 for Q2 2025 and $6.0 million for Q1 2025.